Introducing cholera vaccination in Asia, Africa and Haiti: A meeting report

Abstract Orally-administered cholera vaccine (OCV) has been increasingly examined as an additional tool to intervene against endemic and epidemic cholera. In 2013, short- and long-term field experience with OCV under nine distinctive field settings was reported from India, Bangladesh, Vietnam, Guine...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 33; no. 4; pp. 487 - 492
Main Authors Hall, Robert H, Sack, David A
Format Journal Article Conference Proceeding
LanguageEnglish
Published Netherlands Elsevier Ltd 15.01.2015
Elsevier Limited
Subjects
Acceptability
Administration, Oral
Africa
Allergy and Immunology
Asia
Cholera
Cholera - epidemiology
Cholera - prevention & control
Cholera vaccination
Cholera Vaccines - administration & dosage
Cholera Vaccines - immunology
Clinical Trials as Topic
Disease control
Feasibility
Haiti
Health facilities
Humans
Immunization
Licenses
Oral vaccine
Public health
Studies
Treatment Outcome
Vaccination - methods
Vaccine demonstration
Vaccine stockpile
Vaccines
Haiti
Asia
Africa
Bangladesh
Vietnam
Guinea
Thailand
India
ISW, Bangladesh
ASW, Caribbean Sea, Greater Antilles, Haiti
Thailand, Chacoengsao Prov., Bangkok
ISEW, Vietnam
Cholera vaccination
Cholera
Oral vaccine
Feasibility
Vaccine demonstration
Acceptability
Vaccine stockpile
Online AccessGet full text

Cover

More Information
Summary:Abstract Orally-administered cholera vaccine (OCV) has been increasingly examined as an additional tool to intervene against endemic and epidemic cholera. In 2013, short- and long-term field experience with OCV under nine distinctive field settings was reported from India, Bangladesh, Vietnam, Guinea, Haiti, and Thailand. Lead investigators from each of these projects presented their findings at a symposium chaired by Drs. David A. Sack and Robert H. Hall at the Vaccines for Enteric Diseases (VED) Conference in Bangkok on November 7, 2013. The objective of the symposium was to describe the unique features of each setting and project, share field experience of implementing cholera vaccination, discuss results, and identify constraints to the wider use of OCV. The VED provided a forum where >200 attendees engaged with this exciting and potentially decisive new development in the cholera field.
Bibliography:ObjectType-Conference-1
SourceType-Conference Papers & Proceedings-1
content type line 25
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.11.031